Enlivex Therapeutics (NASDAQ:ENLV) Upgraded at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics (NASDAQ:ENLV) to a strong-buy rating in a research report released on Tuesday, Zacks.com reports.

Separately, HC Wainwright decreased their target price on Enlivex Therapeutics from $7.00 to $6.00 and set a buy rating for the company in a report on Tuesday, June 11th.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $1.30 on Tuesday. Enlivex Therapeutics has a 52-week low of $1.15 and a 52-week high of $4.59. The firm has a market capitalization of $27.13 million, a price-to-earnings ratio of -0.94 and a beta of 0.98. The stock has a fifty day moving average of $1.33 and a 200 day moving average of $2.06.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its earnings results on Friday, June 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.03. Equities analysts forecast that Enlivex Therapeutics will post -0.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Enlivex Therapeutics stock. XTX Topco Ltd purchased a new position in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 24,820 shares of the company’s stock, valued at approximately $35,000. XTX Topco Ltd owned about 0.12% of Enlivex Therapeutics at the end of the most recent reporting period. 1.02% of the stock is currently owned by institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.